ReviewNature reviews. Urology2019
Molecular and histopathology directed therapy for advanced bladder cancer.
Review in Nature reviews. Urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it, 224 citations in OpenAlex.
- Controlling Nutritional Status Score Before Receiving Treatment as a Prognostic Indicator for Patients With Urothelial Cancer: An Exploration Evaluation Methods.Frontiers in oncology · 2021Pooled it
- Three-Dimensional Ultrasound Images in the Assessment of Bladder Tumor Health Monitoring under Deep Learning Algorithms.Computational and mathematical methods in medicine · 2022Trial
- ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53.British journal of cancer · 2026Article
- Bioinformatics analysis and clinical validation identifyTranslational andrology and urology · 2026Article
- Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Comprehensive Complication Index for Assessing Short-Term Complications of Urothelial Carcinoma with Variant Histology: A Patient-Based Study.Annals of surgical oncology · 2026Article
- Genome-wide transcriptional profiling identifies molecular markers associated with early carcinogenesis in high-grade bladder cancer.Scientific reports · 2026Article
- SMK-002 inhibits the growth of bladder cancer cells and increases their sensitivity to OsimertinibThe Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- A high-throughput photothermal aptasensing platform using MnO₂@CuS nanoprobes for noninvasive detection of bladder cancer cells in simulated liquid biopsy.Mikrochimica acta · 2026Article
- Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.Nature communications · 2026Article
- Baicalin chemosensitivity enhancement of cisplatin in bladder cancer via autophagy flux inhibition.Frontiers in pharmacology · 2026Article
- Vitamin D promotes apoptosis and enhances cisplatin sensitivity in bladder cancer cells by inhibiting the Warburg effect through the AKT/mTOR pathway.BMC urology · 2025Article
- Genetic profiling and pathway analysis in bladder carcinoma: Implications for therapeutic targeting.Turkish journal of surgery · 2025Article
- FENDRR represses Bladder Cancer Cell Proliferation, Stemness, Migration, Invasion, and EMT Process by Targeting miR-18a-5p/AFF4 Axis.Biochemical genetics · 2025Article
- Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic biomarker in bladder cancer.Discover oncology · 2025Article
- Liquid Biopsy: Current advancements in clinical practice for bladder cancer.The journal of liquid biopsy · 2025Review
- Identification and validation of a novel signature based on M2 macrophage co-expressed genes in bladder cancer.Translational cancer research · 2025Article
- Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.BMC cancer · 2025Article
- Hypoxia-induced HIF-1α/VASN promotes bladder cancer progression.Scientific reports · 2025Article
- Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification.Journal of translational medicine · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a heterogeneous group of tumours with at least 40 histological subgroups. Patients with localized disease can be cured with surgical resection or radiotherapy, but such curative options are limited in the setting of recurrent disease or distant spread, in which case systemic therapy is used to control disease and palliate symptoms. Cytotoxic chemotherapy has been the mainstay of treatment for advanced bladder cancer, but high-quality evidence is lacking to inform the management of rare subgroups that are often excluded from studies. Advances in molecular pathology, the development of targeted therapies and the resurgence of immunotherapy have led to the reclassification of bladder cancer subgroups and rigorous efforts to define predictive biomarkers for cancer therapies. In this Review, we present the current evidence for the management of conventional, variant and divergent urothelial cancer subtypes, as well as non-urothelial bladder cancers, and discuss how the integration of genomic, transcriptomic and proteomic characterization of bladder cancer could guide future therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.